Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› L'Hospitalet de Llobregat
Clinical trial register · Spain

Clinical Trials in L'Hospitalet de Llobregat, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 111 Madrid 100 Valencia 42 Santiago Compostela 30 Seville 30
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca39 Merck Sharp & Dohme LLC35 Novartis Pharmaceuticals30 Hospital Universitari de Bellvitge27 Pfizer19 Clear sponsor filter
Site location
Barcelona111 Madrid100 Valencia42 Santiago Compostela30 Seville30
All 75 locations
Target enrolment
to

Trials with a site in L'Hospitalet de Llobregat

30 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Recruiting
Novartis Pharmaceuticals
Phase 3
5,700
Santiago Compostela, Seville, Badalona, L'Hospitalet de Llobregat, Santander, Cáceres, Reus, A Coruña
2026-05-11
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
123
Granada, L'Hospitalet de Llobregat, Barcelona, Madrid
2025-12-05
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Albacete, Logroño, Pozuelo de Alarcón, Torrejón de Ardoz, El Palmar
2025-11-11
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Santiago Compostela, L'Hospitalet de Llobregat, Madrid
2025-10-15
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
L'Hospitalet de Llobregat, Oviedo, Barcelona, Madrid, Salamanca
2025-05-30
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Santiago Compostela, L'Hospitalet de Llobregat, Barcelona, Valencia
2024-10-17
Active, closed
Novartis Pharmaceuticals
Phase 1/2
20
L'Hospitalet de Llobregat, Barcelona, Madrid
2024-08-14
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Santiago Compostela, L'Hospitalet de Llobregat, Alicante, Barcelona, Lleida, Madrid, Málaga, Valencia
2024-07-31
Active, closed
Novartis Pharmaceuticals
Phase 1
31
L'Hospitalet de Llobregat, Madrid
2024-07-29
Active, closed
Novartis Pharmaceuticals
Phase 1
42
Granada, Badalona, L'Hospitalet de Llobregat, Madrid
2024-05-15
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Granada, L'Hospitalet de Llobregat, Barcelona, El Palmar, Madrid, Seville, Valencia
2024-03-12
Active, closed
Novartis Pharmaceuticals
Phase 2
49
L'Hospitalet de Llobregat, Barcelona, Madrid
2024-01-03
Recruiting
Novartis Pharmaceuticals
Phase 2/3
232
Palma, Esplugues, L'Hospitalet de Llobregat, A Coruña, Barcelona, Madrid
2023-11-24
Active, closed
Novartis Pharmaceuticals
Phase 1
28
L'Hospitalet de Llobregat, Barcelona, Madrid
2023-11-13
Active, closed
Novartis Pharmaceuticals
Phase 3
109
Santiago Compostela, L'Hospitalet de Llobregat, Santander, El Palmar, Barcelona, Córdoba, Madrid, Salamanca
2023-10-02
Recruiting
Novartis Pharmaceuticals
Phase 4
700
L'Hospitalet de Llobregat, Sabadell, Majadahonda, Barcelona, Madrid, Valencia
2023-08-14
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Santiago Compostela, Badalona, L'Hospitalet de Llobregat, Bilbao, Santa Cruz, Barcelona, Madrid, Seville
2022-08-30
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Santiago Compostela, Vitoria-Gasteiz, L'Hospitalet de Llobregat, Albacete, Barcelona, Logroño, Pozuelo de Alarcón, Torrejón de Ardoz
2021-12-13
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Ferrol, Santiago Compostela, Seville, Mallorca, Palma, el Prat de Llobregat, L'Hospitalet de Llobregat, Sabadell
2021-11-23
Active, closed
Novartis Pharmaceuticals
Phase 3
469
Santiago Compostela, L'Hospitalet de Llobregat, El Palmar, Pamplona, Valencia, Barcelona, Madrid, Málaga
2021-06-15
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
L'Hospitalet de Llobregat, Sabadell, Majadahonda, El Palmar, Barcelona, Madrid, Valencia
2021-06-09
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Santiago Compostela, L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia
2021-02-24
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Santiago Compostela, Málaga, L'Hospitalet de Llobregat, Bilbao, Santander, Vigo, A Coruña, Madrid
2020-12-22
Active, closed
Novartis Pharmaceuticals
Phase 3
19
L'Hospitalet de Llobregat
2020-07-16
Active, closed
Novartis Pharmaceuticals
Phase 1
120
L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia
2019-10-30
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Palma, Pamplona, Sabadell
2019-09-18
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
Badalona, L'Hospitalet de Llobregat, Barcelona, Córdoba, Madrid, Salamanca, Seville, Valencia
2019-06-26
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Cadiz, L'Hospitalet de Llobregat, Barcelona, Donostia / San Sebastian, Salt, Majadahonda, Pozuelo de Alarcón, El Palmar
2018-12-28
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Elche, Granada, Huelva, Jaén, Vitoria-Gasteiz, Badalona, L'Hospitalet de Llobregat, Manresa
2018-12-07
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Esplugues, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia
2015-11-02
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/l-hospitalet-de-llobregat

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies with a site in L'Hospitalet de Llobregat that also match the filters currently applied.

How many clinical trials are recruiting in L'Hospitalet de Llobregat?

12 of the 30 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 18 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (L'Hospitalet de Llobregat), 30 studies
PhaseStudiesRecruitingShare
Phase 314546.7%
Phase 1/26320%
Phase 14013.3%
Phase 43310%
Phase 2206.7%
Phase 2/3113.3%

Most active sponsors

Lead sponsors with the most studies (L'Hospitalet de Llobregat)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals3012
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.